GordonMD Global Investments Officially Launches, Targets Biopharma Investments
GordonMD Global Investments officially launched today. The firm is focused on investments in private and publicly traded biopharma companies primarily located in the U.S., Japan, and Europe; the firm derives its name from Founder Craig Gordon, a licensed physician.
Gordon’s medical knowledge and training combined with his over 10 years of experience at The Capital Group - where he served as an Equity Investment Analyst - built and managed an on average over $7bn AUM portfolio across various mandates, and assisted with oversight of additional multi-billion dollar AUM portfolios.
“The launch of GordonMD Global Investments is the culmination of my decades of experience as a portfolio manager, investment analyst and physician. At GordonMD Global Investments we employ my proprietary analysis to target truly innovative companies with best-in-class assets that move clinically with the potential not only to change the standard of care but also to generate outsized returns. The firm combines my medical and investing acumen to create a singular advantage for institutional and accredited high-net worth investors,” said Craig Gordon, MD, Founder, CEO, and CIO of GordonMD Global Investments.
Prior to The Capital Group, Gordon worked for the Cowen Group in New York as a Biotechnology Equity Research Analyst and Associate; his firms' service providers include Jefferies, Bank of America, SS&C, Seward & Kissel, Constellation Consulting Services, and Goldman Sachs.
© The Sortino Group Ltd
All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or scanning or otherwise, except under the terms of the Copyright, Designs and Patents Act 1988 or under the terms of a licence issued by the Copyright Licensing Agency or other Reprographic Rights Organisation, without the written permission of the publisher. For more information about reprints from AlphaWeek, click here.